Payal Kohli, MD, FACC

home / authors / payal-kohli-md-facc

Articles

Looking Into the Future of Lipid Management

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 11th 2024

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

How to Select Between Available LDL-C Lowering Therapies

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 11th 2024

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Clinical Trial Results on Novel Nonstatins Agents.

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 11th 2024

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Mechanism of Action of Nonstatin Therapies

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 4th 2024

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

The Cumulative Burden of LDL-C

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 4th 2024

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Overcoming Access Barriers to Novel Non Statin Therapies

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh Patel, MD;Pam Taub, MD, FACC, FASPC

December 21st 2023

Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.

Combination Therapy in LDL Lowering

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 21st 2023

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Nonstatin Agents for LDL-C Lowering

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 14th 2023

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

How Low is Too Low in LDL-C?

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 14th 2023

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Matching the Intensity of Treatment to Cardiovascular Risk

C. Michael Gibson, MD;Manesh R. Patel, MD;Payal Kohli, MD, FACC;Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Assessing Cardiovascular Risk in Your Patients

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

Clinical Pearls on Lipid Management

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

The Role of Lipoprotein A in Lipid Lowering

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Long-term efficacy and safety of PCSK9 inhibitors

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

Starting Combination Therapy Early

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

October 5th 2023

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Nonstatin Lipid-Lowering Agents

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

October 5th 2023

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Statin Intolerance

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 28th 2023

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Disparities in Managing Patients

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 28th 2023

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

LDL Cholesterol as a Performance Measure

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 21st 2023

The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.

Reasons for Not Reaching Thresholds

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 21st 2023

The reasons many patients do not reach LDL-cholesterol thresholds.

Real-World Outcomes Data on Failure to Achieve LDL-C Thresholds

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 14th 2023

Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.

Real-World Data on Achieving LDL Thresholds

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 14th 2023

Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.

New Guidance in Lowering LDL-C

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 7th 2023

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

LDL-C and Cardiovascular Disease Risk

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 7th 2023

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.